1
|
Duployez N, Vasseur L, Kim R, Largeaud L, Passet M, L'Haridon A, Lemaire P, Fenwarth L, Geffroy S, Helevaut N, Celli-Lebras K, Adès L, Lebon D, Berthon C, Marceau-Renaut A, Cheok M, Lambert J, Récher C, Raffoux E, Micol JB, Pigneux A, Gardin C, Delabesse E, Soulier J, Hunault M, Dombret H, Itzykson R, Clappier E, Preudhomme C. UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia. Leukemia 2023:10.1038/s41375-023-01906-z. [PMID: 37085611 DOI: 10.1038/s41375-023-01906-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 04/06/2023] [Accepted: 04/17/2023] [Indexed: 04/23/2023]
Abstract
Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that UBTF-TDs occur in about 3% of patients aged 18-60 years, in a mutually exclusive pattern with other known AML subtype-defining alterations. The characteristics of 59 adults with UBTF-TD AML included young age (median 37 years), low bone marrow (BM) blast infiltration (median 25%), and high rates of WT1 mutations (61%), FLT3-ITDs (51%) and trisomy 8 (29%). BM morphology frequently demonstrates dysmyelopoiesis albeit modulated by the co-occurrence of FLT3-ITD. UBTF-TD patients have lower complete remission (CR) rates (57% after 1 course and 76% after 2 courses of intensive chemotherapy [ICT]) than UBTF-wild-type patients. In patients enrolled in the ALFA-0702 study (n = 614 patients including 21 with UBTF-TD AML), the 3-year disease-free survival (DFS) and overall survival of UBTF-TD patients were 42.9% (95%CI: 23.4-78.5%) and 57.1% (95%CI: 39.5-82.8%) and did not significantly differ from those of ELN 2022 intermediate/adverse risk patients. Finally, the study of paired diagnosis and relapsed/refractory AML samples suggests that WT1-mutated clones are frequently selected under ICT. This study supports the recognition of UBTF-TD AML as a new AML entity in adults.
Collapse
Affiliation(s)
- Nicolas Duployez
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France.
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France.
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France.
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France.
| | - Loïc Vasseur
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
| | - Rathana Kim
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Laëtitia Largeaud
- Hematology Laboratory, CHU Toulouse, INSERM 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Marie Passet
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Anaïs L'Haridon
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France
| | - Pierre Lemaire
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Laurène Fenwarth
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
| | - Sandrine Geffroy
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
| | - Nathalie Helevaut
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
| | | | - Lionel Adès
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
| | - Delphine Lebon
- Hematology Department, CHU Amiens-Picardie, Amiens, France
| | - Céline Berthon
- Hematology Department, Claude Huriez Hospital, CHU Lille, Lille, France
| | - Alice Marceau-Renaut
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
| | - Meyling Cheok
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
| | - Juliette Lambert
- Hematology Department, Versailles Hospital, University Versailles-Saint-Quentin-en-Yvelines, Le Chesnay, France
| | - Christian Récher
- Service d'Hématologie, CHU Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Emmanuel Raffoux
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
| | | | - Arnaud Pigneux
- Hematology Department, CHU de Bordeaux, Bordeaux, France
| | - Claude Gardin
- Hematology Department, Avicenne Hospital, AP-HP, Bobigny, France
- Unité 3518, Saint-Louis Institute for Research, Université de Paris, Paris, France
| | - Eric Delabesse
- Hematology Laboratory, CHU Toulouse, INSERM 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Jean Soulier
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Mathilde Hunault
- Hematology Department, Université d'Angers, Université de Nantes, CHU Angers, Inserm, CNRS, CRCI2NA, SFR ICAT, F‑49000, Angers, France
- Fédération Hospitalo-Universitaire, Grand-Ouest Acute Leukemia, Angers, France
| | - Hervé Dombret
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
- Unité 3518, Saint-Louis Institute for Research, Université de Paris, Paris, France
| | - Raphael Itzykson
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
| | - Emmanuelle Clappier
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Claude Preudhomme
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
| |
Collapse
|
2
|
Ducourneau B, Fenwarth L, Duployez N, Lambert J, Struski S, Luquet I, Daudignon A, Helevaut N, Ruminy P, Preudhomme C, Terre C. Cytogenetically masked CBFB-MYH11 fusion and concomitant TP53 deletion in a case of acute myeloid leukemia with a complex karyotype. Leuk Lymphoma 2020; 61:1772-1774. [PMID: 32223488 DOI: 10.1080/10428194.2020.1742905] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Benoît Ducourneau
- Chu de Lille, Laboratory of Hematology, Lille, France.,Laboratory of Hematology, Centre Hospitalier de Valenciennes, Valenciennes, France
| | - Laurène Fenwarth
- Chu de Lille, Laboratory of Hematology, Lille, France.,University of Lille, CNRS, INSERM, Lille, France
| | - Nicolas Duployez
- Chu de Lille, Laboratory of Hematology, Lille, France.,University of Lille, CNRS, INSERM, Lille, France
| | - Juliette Lambert
- Department of Hematology, Centre Hospitalier de Versailles, Le Chesnay, France
| | | | | | | | - Nathalie Helevaut
- Chu de Lille, Laboratory of Hematology, Lille, France.,University of Lille, CNRS, INSERM, Lille, France
| | - Philippe Ruminy
- Institute for Research and Innovation in Biomedicine, Centre Henri Becquerel and Rouen University, Rouen, France
| | - Claude Preudhomme
- Chu de Lille, Laboratory of Hematology, Lille, France.,University of Lille, CNRS, INSERM, Lille, France
| | - Christine Terre
- Laboratory of Hematology, Centre Hospitalier deVersailles, Le Chesnay, France.,Laboratory of Cytogenetics, Centre Hospitalier deVersailles, Le Chesnay, France
| |
Collapse
|
3
|
Duployez N, Chebrek L, Helevaut N, Fournier E, Bemba M, Caillault A, Geffroy S, Preudhomme C. A novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia. Haematologica 2018; 103:e575-e577. [PMID: 29903763 DOI: 10.3324/haematol.2018.190959] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Affiliation(s)
- Nicolas Duployez
- CHU Lille, Laboratory of Hematology .,Univ. Lille, INSERM, UMR-S 1172
| | | | - Nathalie Helevaut
- CHU Lille, Laboratory of Hematology.,Univ. Lille, INSERM, UMR-S 1172
| | - Elise Fournier
- Univ. Lille, INSERM, UMR-S 1172.,CH Dunkerque, Laboratory of Hematology, F-59385
| | - Maxime Bemba
- CH Dunkerque, Hematology Department, F-59385, France
| | | | - Sandrine Geffroy
- CHU Lille, Laboratory of Hematology.,Univ. Lille, INSERM, UMR-S 1172
| | - Claude Preudhomme
- CHU Lille, Laboratory of Hematology.,Univ. Lille, INSERM, UMR-S 1172
| |
Collapse
|
4
|
Ferret Y, Boissel N, Helevaut N, Madic J, Nibourel O, Marceau-Renaut A, Bucci M, Geffroy S, Celli-Lebras K, Castaigne S, Thomas X, Terré C, Dombret H, Preudhomme C, Renneville A. Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. Haematologica 2018; 103:822-829. [PMID: 29472349 PMCID: PMC5927984 DOI: 10.3324/haematol.2017.183525] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2017] [Accepted: 02/16/2018] [Indexed: 12/27/2022] Open
Abstract
Assessment of minimal residual disease has emerged as a powerful prognostic factor in acute myeloid leukemia. In this study, we investigated the potential of IDH1/2 mutations as targets for minimal residual disease assessment in acute myeloid leukemia, since these mutations collectively occur in 15–20% of cases of acute myeloid leukemia and now represent druggable targets. We employed droplet digital polymerase chain reaction assays to quantify IDH1R132, IDH2R140, and IDH2R172 mutations on genomic DNA in 322 samples from 103 adult patients with primary IDH1/2 mutant acute myeloid leukemia and enrolled on Acute Leukemia French Association (ALFA) - 0701 or -0702 clinical trials. The median IDH1/2 mutant allele fraction in bone marrow samples was 42.3% (range, 8.2 – 49.9%) at diagnosis of acute myeloid leukemia, and below the detection limit of 0.2% (range, <0.2 – 39.3%) in complete remission after induction therapy. In univariate analysis, the presence of a normal karyotype, a NPM1 mutation, and an IDH1/2 mutant allele fraction <0.2% in bone marrow after induction therapy were statistically significant predictors of longer disease-free survival. In multivariate analysis, these three variables remained significantly predictive of disease-free survival. In 7/103 (7%) patients, IDH1/2 mutations persisted at high levels in complete remission, consistent with the presence of an IDH1/2 mutation in pre-leukemic hematopoietic stem cells. Five out of these seven patients subsequently relapsed or progressed toward myelodysplastic syndrome, suggesting that patients carrying the IDH1/2 mutation in a pre-leukemic clone may be at high risk of hematologic evolution.
Collapse
Affiliation(s)
- Yann Ferret
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France.,INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France.,University of Lille, F-59000, Paris, France
| | - Nicolas Boissel
- Hematology Department, Saint-Louis Hospital, AP-HP, Paris, France.,EA3518, Institut Universitaire d'Hématologie (IUH), University 7 Paris Diderot, Paris, France
| | - Nathalie Helevaut
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France
| | - Jordan Madic
- Circulating Biomarkers Laboratory, Curie Institute, Paris, France
| | - Olivier Nibourel
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France.,INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France.,University of Lille, F-59000, Paris, France
| | - Alice Marceau-Renaut
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France.,INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France.,University of Lille, F-59000, Paris, France
| | - Maxime Bucci
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France
| | - Sandrine Geffroy
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France
| | - Karine Celli-Lebras
- Acute Leukemia French Association (ALFA) coordination, Saint-Louis Hospital, AP-HP, Paris, France
| | | | - Xavier Thomas
- Hematology Department, Lyon Sud Hospital, Pierre Benite, France
| | - Christine Terré
- Cytogenetic Laboratory, Versailles Hospital, Le Chesnay, France
| | - Hervé Dombret
- Hematology Department, Saint-Louis Hospital, AP-HP, Paris, France.,EA3518, Institut Universitaire d'Hématologie (IUH), University 7 Paris Diderot, Paris, France
| | - Claude Preudhomme
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France.,INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France.,University of Lille, F-59000, Paris, France
| | - Aline Renneville
- Hematology Laboratory, Biology and Pathology Center, CHRU of Lille, France .,INSERM, UMR-S 1172, Cancer Research Institute of Lille, Paris, France.,University of Lille, F-59000, Paris, France
| |
Collapse
|
5
|
Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget 2016; 6:42345-53. [PMID: 26486081 PMCID: PMC4747230 DOI: 10.18632/oncotarget.5645] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Accepted: 10/02/2015] [Indexed: 12/18/2022] Open
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease. Even within the same NPM1-mutated genetic subgroup, some patients harbor additional mutations in FLT3, IDH1/2, DNMT3A or TET2. Recent studies have shown the prognostic significance of minimal residual disease (MRD) in AML but it remains to be determined which molecular markers are the most suitable for MRD monitoring. Recent advances in next-generation sequencing (NGS) have provided the opportunity to use multiple molecular markers. In this study, we used NGS technology to assess MRD in 31 AML patients enrolled in the ALFA-0701 trial and harboring NPM1 mutations associated to IDH1/2 or DNMT3A mutations. NPM1 mutation-based MRD monitoring was performed by RTqPCR. IDH1/2 and DNMT3A mutations were quantified by NGS using an Ion Torrent Proton instrument with high coverage (2 million reads per sample). The monitoringof IDH1/2 mutations showed that these mutations were reliable MRD markers that allowed the prediction of relapse in the majority of patients. Moreover, IDH1/2 mutation status predicted relapse or disease evolution in 100% of cases if we included the patient who developed myelodysplastic syndrome. In contrast, DNMT3A mutations were not correlated to the disease status, as we found that a preleukemic clone with DNMT3A mutation persisted in 40% of the patients who were in complete remission, reflecting the persistence of clonal hematopoiesis.
Collapse
Affiliation(s)
- Houria Debarri
- Hematology Department, Lille University Hospital, Lille, France.,Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France
| | - Delphine Lebon
- Hematology Department, Amiens University Hospital, Amiens, France
| | - Christophe Roumier
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Meyling Cheok
- UMR-S 1172, Team 3, INSERM, Lille, France.,Functional Genomic Platform, Cancer Research Institute, Lille, France
| | - Alice Marceau-Renaut
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Olivier Nibourel
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Sandrine Geffroy
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Nathalie Helevaut
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France
| | | | - Bérengère Gruson
- Hematology Department, Amiens University Hospital, Amiens, France
| | - Claude Gardin
- Hematology Department, Avicenne Hospital, APHP, University Paris 13, Bobigny, France
| | | | - Shéhérazade Sebda
- Functional Genomic Platform, Cancer Research Institute, Lille, France
| | - Martin Figeac
- Functional Genomic Platform, Cancer Research Institute, Lille, France
| | - Céline Berthon
- Hematology Department, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Bruno Quesnel
- Hematology Department, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Nicolas Boissel
- Hematology Department, Saint-Louis Hospital, APHP, Paris, France
| | | | - Hervé Dombret
- Hematology Department, Saint-Louis Hospital, APHP, Paris, France
| | - Aline Renneville
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Claude Preudhomme
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| |
Collapse
|
6
|
Abdelhamid E, Besbes S, Renneville A, Nibourel O, Helevaut N, Preudhomme C, Soua Z. Minimal Residual Disease assessment of IDH1/2 mutations in Acute Myeloid Leukemia by LNA-RQ-PCR. Tunis Med 2016; 94:190-197. [PMID: 27575502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
BACKGROUND With the growing importance of minimal residual disease (MRD) monitoring and the recent discover of IDH mutations in acute myeloid leukemia (AML), the quantification of this molecular marker provides the possibility to monitor the disease progression and the therapy efficacy. OBJECTIVE The aim of this study is to assess the MRD in AML for the first time with IDH1 and IDH2 gene mutations in 15 AML patients. METHODS We have screened R132 IDH1, R140 IDH2 and R172 IDH2 mutations by PCR amplification and direct sequencing and we have quantified them for the first time by RQ-PCR using reverse primers modified by an LNA. A good sensitivity has been obtained. MRD rates obtained by LNA-RQ-PCR were used to draw kinetics of the disease evolution during the follow-up. RESULTS IDH1/2 Results were compared to NPM1 mutation and WT1 over expression and have showed coherent kinetic between MRD rates in 7/11 cases. For the rest, the direct sequencing and the high resolution melting (HRM) assay have confirmed the quantification Results in diagnosis but not in residual samples. CONCLUSION Some optimization will be necessary to improve the mutated allele amplification. The LNA-RQ-PCR might be an easy and less cost method used in a small laboratory for myeloid leukemia MRD assessment using IDH1/2 mutations.
Collapse
|
7
|
Desoutter J, Gay J, Berthon C, Ades L, Gruson B, Geffroy S, Plantier I, Marceau A, Helevaut N, Fernandes J, Bemba M, Stalnikiewicz L, Frimat C, Labreuche J, Nibourel O, Roumier C, Figeac M, Fenaux P, Quesnel B, Renneville A, Duhamel A, Preudhomme C. Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. Leukemia 2015; 30:1416-8. [PMID: 26582646 DOI: 10.1038/leu.2015.314] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- J Desoutter
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - J Gay
- Service d'hématologie clinique, Hôpital Saint Antoine, Université Paris 6, APHP, Paris, France
| | - C Berthon
- Service d'hématologie clinique, CHRU Lille, Université Lille 2, Lille, France
| | - L Ades
- Service d'hématologie clinique, Hôpital d'Avicenne, Université Paris 13, Bobigny, France
| | - B Gruson
- Service d'hématologie clinique, CHU Amiens-Picardie, Amiens, France
| | - S Geffroy
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - I Plantier
- Service d'hématologie clinique, Hôpital de Roubaix, Roubaix, France
| | - A Marceau
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - N Helevaut
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - J Fernandes
- Service d'hématologie clinique, Hôpital de Valenciennes, Valenciennes, France
| | - M Bemba
- Service d'hématologie clinique, Hôpital de Dunkerque, Dunkerque, France
| | - L Stalnikiewicz
- Service d'hématologie clinique, Hôpital de Lens, Lens, France
| | - C Frimat
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - J Labreuche
- Unités de Biostatistiques, CHRU Lille, Université Lille 2, Lille, France
| | - O Nibourel
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - C Roumier
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - M Figeac
- Plateforme de génomique structurale et fonctionnelle, IFR-114, Université Lille 2, Lille, France
| | - P Fenaux
- Service d'hématologie clinique, Hôpital Saint-Louis, Université Paris 7, APHP, Paris, France
| | - B Quesnel
- Service d'hématologie clinique, CHRU Lille, Université Lille 2, Lille, France
| | - A Renneville
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - A Duhamel
- Unités de Biostatistiques, CHRU Lille, Université Lille 2, Lille, France
| | - C Preudhomme
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| |
Collapse
|
8
|
Duployez N, Nibourel O, Marceau-Renaut A, Willekens C, Helevaut N, Caillault A, Villenet C, Celli-Lebras K, Boissel N, Jourdan E, Dombret H, Figeac M, Preudhomme C, Renneville A. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA. Am J Hematol 2014; 89:610-5. [PMID: 24616160 DOI: 10.1002/ajh.23696] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Revised: 02/17/2014] [Accepted: 02/24/2014] [Indexed: 11/10/2022]
Abstract
Although acute myeloid leukemia (AML) with t(8;21) belongs to the favorable risk AML subset, relapse incidence may reach 30% in those patients. RUNX1-RUNX1T1 fusion transcript is a well-established marker for minimal residual disease (MRD) monitoring. In this study, we investigated the feasibility and performances of RUNX1-RUNX1T1 DNA as MRD marker in AML with t(8;21). In 17/22 patients with t(8;21)-positive AML treated in the French CBF-2006 trial, breakpoints in RUNX1 and RUNX1T1 were identified using long-range PCR followed by next-generation sequencing. RUNX1-RUNX1T1 DNA quantification was performed by real-time quantitative PCR using patient-specific primers and probe. MRD levels were evaluated in 71 follow-up samples from 16 patients, with a median of four samples [range 2-7] per patient. RUNX1 breakpoints were located in intron 5 in all cases. RUNX1T1 breakpoints were located in intron 1b in 15 cases and in intron 1a in two cases. RUNX1-RUNX1T1 MRD levels measured on DNA and RNA were strongly correlated (r = 0.8, P < 0.0001). Discordant MRD results were observed in 10/71 (14%) of the samples: in three samples from two patients who relapsed, RUNX1-RUNX1T1 was detectable only on DNA, while RUNX1-RUNX1T1 was detectable only on RNA in seven samples. MRD monitoring on genomic DNA is feasible, but with sensitivity variations depending on the patient breakpoint sequence and the qPCR assay efficiency. Although interpretation of the results is easier because it is closely related to the number of leukemic cells, this method greatly increases time, cost and complexity, which limits its interest in routine practice.
Collapse
Affiliation(s)
- Nicolas Duployez
- Laboratory of Hematology; Biology and Pathology Center; Lille France
| | - Olivier Nibourel
- Laboratory of Hematology; Biology and Pathology Center; Lille France
- Inserm U-837, Team 3; Cancer Research Institute; Lille France
| | - Alice Marceau-Renaut
- Laboratory of Hematology; Biology and Pathology Center; Lille France
- Inserm U-837, Team 3; Cancer Research Institute; Lille France
| | | | - Nathalie Helevaut
- Laboratory of Hematology; Biology and Pathology Center; Lille France
| | - Aurélie Caillault
- Laboratory of Hematology; Biology and Pathology Center; Lille France
| | | | | | - Nicolas Boissel
- Department of Adult Hematology; St. Louis Hospital; Paris France
| | - Eric Jourdan
- Department of Hematology and Oncology; Nîmes University Hospital; Nîmes France
| | - Hervé Dombret
- Department of Adult Hematology; St. Louis Hospital; Paris France
| | | | - Claude Preudhomme
- Laboratory of Hematology; Biology and Pathology Center; Lille France
- Inserm U-837, Team 3; Cancer Research Institute; Lille France
| | - Aline Renneville
- Laboratory of Hematology; Biology and Pathology Center; Lille France
- Inserm U-837, Team 3; Cancer Research Institute; Lille France
| |
Collapse
|
9
|
Abdelhamid E, Figeac M, Renneville A, Quief S, Villenet C, Boyer T, Nibourel O, Coiteux V, Cassinat B, Lippert E, Helevaut N, Soua Z, Preudhomme C. Quantification of JAK2V617F mutation by next-generation sequencing technology. Am J Hematol 2013; 88:536-7. [PMID: 23553621 DOI: 10.1002/ajh.23446] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2013] [Revised: 03/25/2013] [Accepted: 03/25/2013] [Indexed: 11/08/2022]
Affiliation(s)
| | | | | | | | | | - Thomas Boyer
- Laboratoire d'Hématologie, Centre de Biologie-Pathologie; CHRU de Lille; Lille; France
| | | | - Valerie Coiteux
- Laboratoire d'Hématologie, Centre de Biologie-Pathologie; CHRU de Lille; Lille; France
| | - Bruno Cassinat
- Unité de Biologie Cellulaire, Hoˇpital Saint-Louis; Paris; France
| | - Eric Lippert
- Laboratoire d'Hématologie, CHU de Bordeaux, U1035, Université Bordeaux; Bordeaux; France
| | | | - Zohra Soua
- U.R. “Biologie Moléculaire des leucémies et lymphomes”, Faculté de Médecine de Sousse, Université de Sousse; Tunisia
| | | |
Collapse
|
10
|
Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton SD, Revel TD, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia 2012; 26:1247-54. [DOI: 10.1038/leu.2011.382] [Citation(s) in RCA: 108] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|